A case for the adoption of pharmacoeconomic guidelines in Japan

PharmacoEconomics

Volumn 10, Issue 6, 1996, Pages 546-551

  Ikeda, Shunya ^a   Ikegami, Naoki ^a   Oliver, Adam J ^a   Ikeda, Mie ^b  

^a KEIO UNIVERSITY   (Japan)

^b Japan Ministry of Health Labour and Welfare   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; JAPAN; PHARMACOECONOMICS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0029821999     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199610060-00003     Document Type: Short Survey

References (16)

1. Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee, including major submissions involving economic analyses. Canberra: Australian Government Publishing Service, Nov 1995
2. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. 1st ed. Ottawa: CCOHTA, Nov 1994
3. Drummond MF, Rutten F, Brenna A, et al. Economic evaluations of pharmaceuticals: a European perspective. Pharmacoeconomics 1993; 4: 173-86
4. Inoue S, Kitazawa S, Oliver A, et al. Present situation of pharmacoeconomic evaluation by Japanese pharmaceutical companies [abstract P6]. First Annual International Meeting for the Association for Pharmacoeconomics and Outcomes Research: 1996 May 12; Philadelphia
5. Ikegami N. Pharmaceutical prices, quantities and innovation: comparing Japan with the US. Pharmacoeconomics 1994; 6: 424-33
6. The Ministry of Health and Welfare. Administrative Announcement; 30 September 1994. Tokyo: Ministry of Health and Welfare, 1994
7. Freemantle N, Maynard A. Something rotten in the state of clinical and economic evaluations. Health Econ 1994; 3: 63-7
8. Mason J, Drummond M. Reporting guidelines for economic studies. Health Econ 1995; 4: 85-94
9. Briggs A, Sculpher M. Sensitivity analysis in economic evaluation: a review of published studies. Health Econ 1995; 4: 355-71
10. Ikeda S, Noguchi N, Oliver A, et al. A review of pharmacoeconomic studies in Japan [abstract C27]. First Annual International Meeting for the Association for Pharmacoeconomics and Outcomes Research: 1996 May 12; Philadelphia
11. Moriga M, Ikeda S, Reich MR. An analysis of pharmacoeconomic studies in Japan [in Japanese]. Iryo Keizai Kenkyu 1995; 2: 73-83
12. Clemens K, Townsend R, Luscombe F, et al. Methodological and conduct principles for pharmacoeconomic research Pharmacoeconomics 1995; 8: 169-74
13. Drummond MF. Guidelines for pharmacoeconomic studies: the ways forward. Pharmacoeconomics 1994; 6: 493-7
14. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987
15. Gold, MR, Siegel, JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
16. Society of Japanese Pharmacopoeia, editor. Guidelines for the clinical evaluation for new drugs 1995 [in Japanese]. Tokyo: Yakuji Nippo, 1995